A single center, retrospective study of short-term outcomes in patients with kidney transplant receiving de novo belatacept with anitu-tymocyte globulin

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Antithymocyte globulin (Primary) ; Basiliximab (Primary) ; Belatacept (Primary)
Indications Renal transplant rejection
Focus Adverse reactions

13 Jul 2020 New trial record
03 Jul 2020 Primary endpoint (infectious outcome: viral infection requiring hospitalization within 3 months post-transplant) has not been met.
03 Jun 2020 Primary endpoint (composite allograft endpoint: biopsy proven acute rejection (BPAR), death or graft loss) has not been met.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com